Again and again I have mentioned the huge need we have for the development of reliable bio-markers. Reliable bio-markers will allow us to know which men will respond positively to a treatment (also those who will not) and when a treatment is still effective (also when it no longer is effective). These biomarkers really don’t [...]
Yesterday’s post described research performed at Northwestern University that found a sharp increase in the number of men diagnosed with advanced aggressive prostate cancer between 2004 and 2013. The research interpretation raised the possibility that the United States Preventive Task Force (USPTF) decision to recommend against the use of the PSA test for prostate cancer [...]
According to information from a published report from the Tuesday, July 19, 2016 edition of HealthDay News, there has been an explosion of new cases of advanced prostate cancer in the United States. They reported on a study using data on nearly 800,000 men listed in the National Cancer Data Base who had been diagnosed [...]
There are multiple definitions of biochemical recurrence for prostate cancer treatment post surgery. This causes confusion both within the patient community and the medical community. It would be very helpful if we could standardize a simple measure, PSA as the biomarker for a biochemical recurrence. Standardization post surgery would give us a better way to [...]
Historically, too many men were haphazardly treated for prostate cancer. Happily, the incidents of over treatment have been declining and the general acceptance of Active Surveillance has emerged as the preferred management strategy for men with very low–risk prostate cancer. However, There is still too few high-quality comparative effectiveness studies evaluating the incremental risks associated [...]